reMYND

• A study to investigate safety and effectiveness of REM0045392 compared with placebo in healthy elderly participants and participants with Alzheimer’s disease

  Phase 1, Not yet recruiting, 34 people, 28 Sept 2026

Sources: euclinicaltrials.eu

• Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications

  Consulting or advice, 24 Sept 2026

• Longitudinal Associations of Multimodal Core 1 Alzheimer Disease Biomarkers With Cognition in Aging and Preclinical Alzheimer Disease

  Consulting or advice, Board or leadership role, 17 Oct 2025

• Plasma p-tau217 identifies cognitively normal older adults who will develop cognitive impairment in a 10-year window

  Consulting or advice, Board or leadership role, 1 Feb 2025

• Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  Consulting or advice, Fees or honoraria, Board or leadership role, 1 Mar 2024

• Diagnostic accuracy of the plasma ALZpath pTau217 immunoassay to identify Alzheimer's disease pathology

  Consulting or advice, Board or leadership role, 12 Jul 2023

• Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease

  Consulting or advice, Board or leadership role, 1 Jun 2023

Sources: pubmed.ncbi.nlm.nih.gov